Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Standard BioTools Inc
LAB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.6290
-0.0294
-4.47%
Ult. Agg.: Oct 15, 9:26 AM
$0.6320
-0.0264
-4.01%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Standard BioTools Financials
Standard BioTools (LAB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Standard BioTools Q2 EPS $(0.07) Misses $(0.03) Estimate, Sales $20.104M Miss $20.805M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 22.22 percent increase over losses of $(0.09) per share
Benzinga Newsdesk
PRO
Standard BioTools Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $81.504M Est
Standard BioTools (NASDAQ:LAB) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $81.504 million estimate.
Benzinga Newsdesk
PRO
Standard BioTools Q1 EPS $(0.04) Beats $(0.06) Estimate, Sales $21.146M Beat $17.914M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.06) per share from
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
Standard BioTools Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
Standard BioTools Sees FY2026 Sales $80.000M-$85.000M vs $79.727M Est
Benzinga Newsdesk
